title: Tamoxifen as first-line treatment in a premenarchal girl with juvenile breast hypertrophy.
abstract: BACKGROUND
  Juvenile breast hypertrophy is uncommon and is characterized by excessive breast enlargement in the peripubertal period. The clinical entity is thought to result from increased sensitivity of mammary tissue to normal levels of circulating hormones.
  
  
  METHODS
  Here, we report a female patient, aged 12 years and 6 months, suffering from juvenile breast hypertrophy, who presented at the third month of symptoms and benefited from tamoxifen treatment.
  
  
  CONCLUSIONS
  In experienced clinics, use of tamoxifen in the treatment of juvenile breast hypertrophy during the brisk growth period may become a medical alternative to reconstructive surgery.
authors.affiliation: Department of Pediatric Endocrinology, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey.
authors.forename: Korcan
authors.initials: K
authors.lastname: Demir
authors.forename: Tolga
authors.initials: T
authors.lastname: Unuvar
authors.forename: Sanem
authors.initials: S
authors.lastname: Eren
authors.forename: Ayhan
authors.initials: A
authors.lastname: Abaci
authors.forename: Ece
authors.initials: E
authors.lastname: Bober
mesh_terms: D001940:Breast / Q000002:abnormalities / Q000473:pathology*; D002648:Child; D005260:Female; D006801:Humans; D006984:Hypertrophy / Q000188:drug therapy; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use*; D013629:Tamoxifen / Q000627:therapeutic use*
chemical_list: D020845:Selective Estrogen Receptor Modulators; D013629:Tamoxifen